Intercede Group PLC Preliminary Results: Resilient Performance Amid US Federal Delays, Strong Order Momentum into FY27

US Federal procurement delays and FY27 order momentum: timing issue or warning sign?

This is the main debate in the whole announcement. Management says FY26 was hit by US Federal procurement delays linked to geopolitical uncertainty, and the Board believes those opportunities were delayed, not lost.

That explanation would be easy to dismiss if nothing happened after the year end. But Intercede has backed it up with post year-end contract news. It announced approximately $5.2 million of renewals and new orders on 9 April 2026, then a further approximately $3.8 million on 21 April 2026.

The standout contract in that second announcement was a US Federal Agency MyID CMS perpetual licence upsell of approximately $3.6 million. A perpetual licence means the customer pays for long-term use of the software upfront rather than via a subscription. That is good for near-term revenue, although subscriptions are usually better for long-term visibility.

My read is fairly simple. The timing explanation looks credible, but it still highlights a weakness in the model: Intercede remains exposed to large customer decisions, especially in the US Federal market. When procurement slows, numbers can wobble.

Intercede profitability and cash generation: still strong, but margins softened

Gross profit fell to £16.4 million from £17.2 million, and gross margin eased to 95.3% from 97.2%. In most sectors that would still be an eye-watering margin. In software, it shows the core economics remain very attractive.

Operating profit dropped to £3.2 million from £3.9 million, while adjusted EBITDA came in at £4.0 million versus £4.5 million. Net margin was 19.8%, down from 23.2%. So yes, profitability softened, but this is still a solidly profitable business.

The cash performance is arguably the most reassuring part of the release. Cash and cash equivalents increased to £20.0 million, net cash from operating activities rose to £3.1 million, and the company remained debt-free. For a small-cap tech name, that balance sheet gives Intercede options and reduces financial risk.

There was, however, a £1.8 million cash outflow for a cash-settled share-based payment in financing activities. Investors should not ignore that. It does not undermine the balance sheet, but it is a real cash movement and worth noting.

Intercede strategy in cybersecurity identity software: sensible ambition, early AI use, disciplined M&A

Strategically, the company is trying to evolve from employee identity into broader enterprise credential management across people, machines and agentic AI. That is ambitious, but it is at least adjacent to what Intercede already does rather than some random pivot.

Product delivery looks steady. The company delivered nine product releases in FY26, including four MyID CMS releases, three MyID MFA and PSM releases, and MyID SecureVault v3.0. Customer Net Promoter Score improved to +58 from +55, which suggests customers are generally happy with the products and support.

I also like the tone on AI. Intercede is using AI internally to improve software development and marketing productivity, but it is not pretending AI is a magic wand. The company says AI-assisted output is reviewed by qualified colleagues and kept inside its own controlled environment. In cybersecurity, that cautious approach is exactly what you want to hear.

On acquisitions, the Board says it engaged with over 25 potential targets during FY26 but stayed disciplined on price and fit. With £20.0 million in cash and no debt, Intercede has firepower. The positive is optionality. The risk is that acquisitions can distract if management gets too eager.

Intercede risks for investors: no dividend, lower deferred revenue, US concentration still matters

This was not a perfect update. Profit before tax, net profit and earnings per share all moved lower. Deferred revenue fell to £8.1 million from £8.8 million, and current deferred revenue dropped to £7.4 million from £8.1 million due to delayed support and maintenance renewals. Deferred revenue is money billed in advance and often gives a clue about future revenue visibility, so a decline is not ideal.

There is also no dividend proposed. That is not a problem if investors want reinvestment and growth, but income seekers will have to look elsewhere.

Geographically, the Americas remain dominant at £14.1 million of revenue, up from £13.5 million. That concentration can be a strength because Intercede has deep US Federal relationships, but it also makes the business more sensitive to procurement delays in that market.

What Intercede FY26 results mean for retail investors

My overall take is mildly positive. This was not a blowout year, but it was a resilient one. A profitable cybersecurity software company with £20.0 million of cash, no debt, rising recurring revenue and decent early FY27 order momentum is in a stronger position than the modest revenue decline might suggest.

The key question now is whether FY27 converts that momentum into cleaner top-line growth. If the delayed orders really were timing-related, Intercede has a good chance of bouncing back. If delays keep recurring, investors may start to treat them as a feature of the business rather than a one-off excuse.

For now, the story remains intact. Intercede looks financially sturdy, strategically focused and commercially credible – but it still needs FY27 to prove that the recent order announcements are the start of renewed growth, not just a temporary catch-up.